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INTRODUCTION: 
Multiple organ dysfunction syndrome (MODS) is a 
continuum, with incremental degrees of physiologic 
derangements in individual organs; it is a process rather 
than a single event. Alteration in organ function can vary 
widely from a mild degree of organ dysfunction to 
completely irreversible organ failure. It is the unwanted 
outcome of successful shock resuscitation. Shock is an 
insufficient perfusion of organ, inspite of adequate fluid 
resuscitation, usually prevent a steady hypotension or 
require vasoactive drugs to raise blood pressure.  
MODS is widely considered to be the leading cause of 
morbidity and mortality for patients admitted to an ICU1-
4.However, despite its immediate and infinitely 
recognizable manifestations in the critically ill patient, its 
characterization as a discrete syndrome with a common 
and measurable pathologic basis has been problematic. 
First, patients admitted to an ICU frequently have some 
degree of preexisting physiologic impairment, so that it 
may be difficult to differentiated rangements that are 
acute and potentially reversible from those that 
arechronic and irreversible. Second, the spectrum of 
disorders that lead to ICU admission commonly includes 
diseases that cause direct organ injury, for example, 
pneumonia or trauma producing acute lung injury, or 
mesenteric vascular ischemia causing liver dysfunction. 
Finally, the challenge in characterizing organ 
dysfunction in biochemical terms has been not a lack of 
definable abnormalities, but a surplus of it. Literally 
hundreds of biochemical and cellular abnormalities have 
been described in patients with MODS, and their very 
number has made it difficult, if not impossible, to define 
a single common underlying event or process as the 
pathogenic basis of the disorder. In fact, it is not yet clear 
whether MODS is a single pathologic process with 
highly variable clinical expression or simply the limited 
phenotypic expression of a large number of 
pathologically divergent processes. This paper will 
review the more prominent theories about the 
pathogenesis of MODS, recognizing that the mechanisms 
that have been proposed are by no means exclusive and 
are often best viewed as differing perspectives on 
common pathologic processes. 
 
ABSTRACT 
Objective: To review multiple organ dysfunction syndrome with respect to: 1) clinical and preclinical measurement systems; 
2) Interventions/ Model system used 3) pathophysiology and 4) Various therapeutic implications. 
Methods: The Medline, Pubmed, Pubmed Central and Science Direct, conference proceedings, bibliographies of review 
articles were searched for relevant articles. Key index words were multiple organ failure, multiple system organ dysfunctions , 
sepsis, septic shock, shock, systemic inflammatory response syndrome. Outcomes prospectively defined were death and 
physiological reversal of end organ failure. 
Results: Multiple organ dysfunction/failure (MODS) is very colloquial cause for death in intensive care units. With early 
resuscitation, it was possible to save life otherwise it would have been hard to save one. It occurs due to the unconstrained 
systemic inflammation and varied etiologies. As of now, there is no therapy which can prevent or improve MODS with  
dramatic favourable outcomes. 
Conclusion: Multiple organ dysfunctionmay serve as a useful way to check disease severity for improved quality of care and 
therapy. Shock patient streated by Anesthesiologists will take into consideration subsequent development of MODS in the 
critical care unit and may be required to provide anesthetic support to these patients. 
Keywords: Aberrant Cellular Signalling, Multiple Organ Failure 
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Figure1. Illustrates the basic pathway involved in multi organ dysfunction, infected with an pathogen 
 
It is also defined as the presence of altered organ 
function in an acutely ill patient such that homeostasis 
could not be maintained without intervention. It also was 
recognized that the initial injury may produce direct 
organ system injury or be accompanied by hemodynamic 
alterations, such as hypotension and/or decreased cardiac 
output, which could result in organ dysfunction/failure5. 
This condition has been termed primary MODS. 
Secondary MODS is the term used to describe the onset 
of organdies function/failure that develops later in the 
course of illness and is frequently related to shock and 
sepsis5. 
It is a progressive condition normally characterized by 
combined failure of several major organ systems in a 
critically ill individual that can make it impossible to 
maintain homeostasis without some type of medical 
intervention and which is normally a complication of 
sepsis and is also a major factor in predicting mortality. 
It normally involves the collapse of at least two organ 
systems. MODS may include any of these listed vital 
systems: 
 Respiratory 
 Renal 
 Cardiovascular 
 Neurologic 
 Hepatic 
 Hematologic 
The signs and symptoms of end-organ dysfunction in the 
above organ systems consist of: 
Lung or respiratory system – will show a dysfunction 
of normal exchange of gas, revealed mainly in “arterial 
hypoxemia” which is insufficient oxygen getting into the 
blood system. Many pathologic features add to this 
impaired gas exchange. 
Kidney or renal system – is revealed in the impairment 
of the normal selective excretory function first in oliguria 
or low output of urine despite adequate intravascular 
volume, but later in a rising creatinine level and 
electrolyte and fluid problems of sufficient magnitude 
that in some cases dialysis may be required. 
Heart and cardiovascular system – dysfunction of this 
system consist of abnormalities predisposed to impaired 
delivery of oxygen and therefore contribute to the injury 
of other organ systems. 
Hepatic system – dysfunction of the hepatic system is 
reflected in excess bilirubin circulating in the blood as 
well as lack of bile flowing from the liver. 
Neurologic system – there is an altered level of 
consciousness, which is reflected in the reduction in the 
Glasgow Coma Score which is the scale of 
consciousness of a individual due to multiple causes 
Hematologic system – the most widely cited 
manifestation of dysfunction of the blood system consist 
of thrombocytopenia which in critical illness is cause by 
a multiple of factors. 
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Criteria for Organ Dysfunction: 
Organ System Mild Criteria Severe Criteria 
Pulmonary Hypoxia or hypercarbia necessitating assisted 
ventilation for 3-5 days 
ARDS requiring PEEP >10 cm H2 O 
and FI O2< 0.5 
Hepatic Bilirubin 2-3 mg/dL or other liver function 
tests >2 × normal, PT elevated to 2 × normal 
Jaundice with bilirubin 8-10 mg/dL 
Renal Oliguria (< 500 mL/day) or increasing 
creatinine (2-3 mg/dL) 
Dialysis 
Gastrointestinal Intolerance of gastric feeding for more than 5 
days 
Stress ulceration with need for 
transfusion, acalculouscholecystitis 
Hematologic aPTT>125% of normal, platelets < 50-80,000 DIC 
Cardiovascular Decreased ejection fraction with persistent 
capillary leak 
Hyperdynamic state not responsive to 
pressors 
CNS Confusion Coma 
Peripheral nervous system Mild sensory neuropathy Combined motor and sensory deficit 
 
  
aPTT = activated partial thromboplastin time; ARDS = acute respiratory distress syndrome; CNS = central nervous system; DIC = 
disseminated intravascular coagulation; FI O2 = fraction of inspired oxygen; PEEP = positive end-expiratory pressure; PT = 
prothrombin time. 
  
   
     Organ system        0          1        2         3         4 
Respiratorya 
(PO2/FIO2 Ratio) 
>300    
 
226–300 151–225 76–150   ≤ 75 
Renalb 
(Serum Creatinine) 
≤ 100 101–200 201–350 351-500 > 500 
Hepaticc 
(Serum Bilirubin) 
≤ 20 21–60 61–120 121–240 > 240 
Cardiovasculard 
(R/P Ratio) 
≤ 10.0 10.1–15.0 15.1-20.0 20.1–30.0 > 30 
Hematologice 
(Platelet count) 
> 120 81–120 51–80 21–50   ≤ 20 
Neurologicf 
(Glasgow Coma Score) 
15 13–14 10–12 7–9   ≤ 6 
 
  
a. The PO2/FIO2 ratio is calculated without reference to the use or mode of mechanical ventilation, and without reference to the use 
or level of PEEP. 
b. The serum creatinine level is measured in μmol/liter, without reference to the use of dialysis. 
c. The serum bilirubin level is measured in μmol/liter. 
d. The R/P ratio is calculated as the product of the heart rate and right atrial (central venous) pressure, divided by the mean arterial 
pressure:  
                  
e. The platelet count is measured in platelets/mL 10-3 
 
  
MODS scoring systems can be classified using general 
physiological critical care scores i.e., Acute 
Physiological and Chronic Health 
Evaluation;(APACHE), Simplified Acquired 
Physiological Score (SAPS), Mortality Probability 
Model (MPM) 6 or specific organ score to describe 
dysfunction/failure (i.e., Multiple organ dysfunction 
score; MODS), Sepsis related Organ Failure Assessment 
(SOFA), Logistic Organ Dysfunction System CLODS). 
The specific organ dysfunction scores classify organs as 
failed (i.e., yes or no) or dysfunctional using an ordinal 
scale (i.e., graded score)7,8. The aggregate score 
quantitates severity in any one organ and the overall 
severity of organ dysfunction. The aggregate score can 
then be interpreted as a likelihood of predicted mortality 
based upon the observed mortality in those study patients 
used to construct the original scoring system. Ideally, 
scoring systems should be simple, demonstrate good 
inter and intra observer reliability, be generalizable over 
time and in different intensive care units, and be 
independent of therapyprovided9. 
INCIDENCE AND EPIDEMIOLOGY  
Given the difficulties with accepted definitions, it is not 
surprising that the actual incidence of MODS/MOF is 
unknown. In part, this uncertain incidence is related to 
lack of a uniformly accepted definition, but there also is 
uncertainty concerning how to factor in pre-existing 
organ dysfunction/ failure. Major risk factors include 
sepsis and the systemic inflammatory response syndrome 
(SIRS), shock and prolonged periods of hypotension, 
trauma, bowel infarction, hepatic dysfunction, increased 
age, and alcohol abuse. Nonetheless, MODS / MOF is 
currently  recognized as a major cause of mortality in 
SIRS, trauma, sepsis, the  acute respiratory distress 
syndrome (ARDS), and other critical illnesses10-17. 
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CELLULAR MECHANISMS 
The frequent association of MODS/MOF with sepsis, 
SIRS, ARDS,  and other inflammatory processes 
suggests that there may be a causal  link to the complex 
pathophysiologic processes that are characteristic of  
SIRS.18-23, Recent evidence has suggested that the SIRS 
response  is rapidly followed in most patients by a 
compensatory anti-inflammatory response limit the SIRS 
response so that it is not counterproductive10. The 
subsequent balance between the proinflammatory(SIRS) 
and anti-inflammatory (CARS) response has been 
referred to as the mixed antagonistic response syndrome 
or MARS10.Typically, this delicate balance is difficult to 
achieve and there is a predominance of either the 
inflammatory response or the anti-inflammatory 
response. Does excessive inflammatory reaction, organ 
dysfunction is likely to ensue?; when there is an 
excessive anti-inflammatory response, the patient is at 
risk for opportunistic or secondary infections? 
Development of subsequent infections may serve as an 
additional insult to again trigger the SIRS response. 
There are a variety of potential mediators for the injury 
process seen in sepsis and other causes of SIRS5,17,18,21,23-
31. A number of the potential humoral, cellular, and 
exogenous mediators are listed below: 
 
Potential   Humoral   Mediators: 
 ComplementArachidonicAcid  Metabolic products 
 Lipoxygenase   products 
 Cyclooxygenase   products 
 Tumor  Necrosis  Factor 
 Interleukins (1-13) 
 Growth  Factors 
 Adhesion   Molecules 
 Platelet  Activating  Factor 
 Procoagulants 
 Fibronectin  andOpsonins 
 Toxic Oxygen  Free Radicals  
 Endogenous   Opioids-Endorphins 
 Vasoactive  Polypeptides   and  Amines  
 Bradykinin  and  Other  Kinins 
 Neuroendocrine Factors 
 Myocardial  Depressant   Factor 
 Coagulation   Factors  and  Their  Degradation   
Product 
Cellular   Inflammatory   Mediators  
 Polymorphonuclear Leukocytes  
 Monocytes/Macrophages  
 Platelets 
 Endothelial   Cells 
Exogenous   Mediators 
 Endotoxin 
 Exotoxin  and  Other  Toxins 
 
 
 
The humoral   mediators   include  components   of the 
complement   system, products  of arachidonic  acid 
metabolism  (both  lipoxygenase  and cyclooxygenase  
metabolites),   tumor  necrosis  factor  (TNF), 
interleukins (IL 1-15), various growth factors, adhesion 
molecules, platelet  activating factor (PAF), nitric 
oxide, procoagulants, fibronectin and opsonins, toxic 
oxygen free radicals, endogenous opiods (endorphins), 
vasoactive polypeptides and amines, bradykinin and 
other kinins, neuroendocrine factors, myocardial 
depressant factor, and coagulation factors and their 
degradation products. The fact that there is no single 
pathway for organ system dysfunction/ failure makes 
treatment extremely difficult and has generated the 
current enthusiasm toward defining methods of 
prevention.
 
 
Figure 2: Elaborates the role of various mediators involved and final outcome as multi organ failure. 
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Comprehensive Interventions studied and various mechanisms involved 
S.no 
 
Model name 
 
Intervention studied 
 
Pathway Mechanism 
 
1. Altered chemokine response in an animal model of 
multiple organ dysfunction syndrome induced by 
zymosan32 
Role of Chemoattractans 
 
Elevated MCP-1, 
locally and 
systematically 
2. The zymosan-induced generalized inflammation 
(ZIGI) model33 
Role of TNF-α, LT-α  
 
Generalised 
Inflammation 
3. Elucidation of the early events contributing to 
zymosan-induced multiple organ dysfunction 
syndrome using MIP-1alpha, C3 knockout, and C5-
deficient mice34 
Role of Macrophage 
inhibitory protein, 
complement system in Multi 
organ failure 
Zymosan induced 
inflammation 
 
4. Protective effect of N-acetylcysteine on multiple 
organ failure induced by zymosan in the rat.35  
Anti-inflammatory role of N-
acetylcysteine 
 
Regulates pro-
inflammatory profile  
via NF-KB signalling  
5. Protective effect of poly(ADP-ribose) synthetase 
inhibition on multiple organ failure after zymosan-
induced peritonitis in the rat.36  
Aminobenzamide,      
Nicotinamide 
 
PARS inhibitor  
 
6. Classical corticosteroids and new lipid peroxidation 
inhibitors in the therapy of multiple organ failure 
(MOF) 37 
Dexamethasone, 
Antioxidants 
 
Inhibition of Lipid 
Peroxidation reaction 
 
7. Protective effect of melatonin in a non-septic shock 
model induced by zymosan in the rat.38  
 
 
Role of Melatonin, an 
antioxidant harmone   
 
Scavenger of 
hydroxyradicals, 
peroxynitrate, inhibition 
of NO production 
8. Study on delay two-phase multiple organ 
dysfunction syndrome.39  
 
 
Study of injury factors, 
pathogenic process and 
clinical features of delay 
two-phase multiple organ 
dysfunction 
syndrome (MODS) 
Inflammatory processes 
 
9. A pathological study of goat multiple organ failure 
model40 
 
Inflammatory cell 
infiltration, spotty 
parenchyma 
LPS mediated 
endotoxemia 
 
10. Animal model of non-bacteriaImuItipIe organ 
dysfunction syndrome in the elderly41 
 
Importance of Lungs in 
zymosan induced MODS 
compared to other organs 
like brain, heart, liver and 
kidney. 
Activation of 
Compliment and 
Macrophage leading to 
inflammation 
 
Inflammation has become the most current etiological 
explanation of MODS. It is the activation of circulating 
cells (leukocytes), the endotheliurm, the liver, and 
multiple mediator networks that are normally held in 
balance by corresponding anti-inflammatory mediators. 
Chemotactic agents attract, adhesion molecules focus, 
and cytotoxic agents assist these cells in driving the 
process. MODS (see Figure 2) occurs when either the 
host's inflammatory or anti-inflammatory response to 
injury (or both) are excessive; death may occur if the 
host response to injury is either excessive or 
insufficient42. In broad terms, following a noxious insult 
there is an initial response mediated by liver, neutrophils, 
macrophages and the endothelium. Hepatic inflammatory 
proteins such as C reactive protein are opsonins of 
degraded proteins and nucleic acids derived from injured 
cells which would be potentially metabolized to more 
toxic substances43.The macrophage response includes the 
release of a variety inflammatory mediators (e.g., Tumor 
Necrosis Factor [TNF], Interleukin 1, Interleukin 6); 
these mediators then up regulate receptors on neutrophils 
(e.g., L Selectin) and endothelial cells (e.g., P Selectin, E 
Selectin, Intercellular Adhesion Molecule 1, Vascular 
Cell Adhesion Molecule 1Cellular) and stimulate 
transmigration. Adhesion molecules can be considered as 
aids to the retention of neutrophils as these large cells are 
transiently retained in the microvasculature by purely 
mechanical factors 44. With transmigration other effect or 
molecules (reactive free radical species, endopeptidases) 
are released that cause organ damage and further recruit 
activated neutrophilsto the site of injury 45. 
Cytokines are important inflammatory mediators with 
the following actions: 1) directing a T lymphocyte 
response; 2) inducing enzyme production in distant sites 
(e.g., endothelium: nitric oxide, liver: C reactive protein); 
and 3) altering cell surface adhesion molecules.  
The theoretical intervention points for MODS 
therapy 
1) Cell adhesion retardation 2) inflammatory mediator 
reduction (translation/transcription inhibition); 3) 
neutralizing (polyclonal or monoclonal) antibodies 
directed at cytokine/ vasoactive /coagulation / 
complement mediators: 4) cytokine/vasoactive / 
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complement / coagulation mediator receptor 
inhibitors: 5) anti inflammatory protein induction 
(preconditioning, substrates, products, or genes); and 
6) anti-oxidants and anti-proteases46. 
CONCLUSION 
Initiation of inflammation has been the key role in sepsis. 
Its prolongation is often associated with other biological 
cascade. Early recognition and measures to prevent it, 
will be vital. Otherwise, dramatic sequential events will 
occur, ultimately causing rise in mortality. A strong 
stand is required in the development of sepsis mimicking 
models. Since the initiated inflammation associated 
sepsis may or may not lead to multiple organ dysfunction 
and the death of the animal might be the result of some 
miscellaneous reasons. Over the past years, considerable 
amount of efforts have been put in, to comprehend the 
pathophysiology of sepsis and subsequently multiple 
organ dysfunction. So, I would like to conclude that new 
therapies to the existing therapies and new multiple 
organ dysfunction model systems are need of the hour.
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